The nation of Zimbabwe has declined a significant US health deal valued at $367m (272 million pounds) spanning five years over the United States' request for sensitive data.
This move came to light after a government memo dated December was disclosed, indicating that President Emmerson Mnangagwa felt the arrangement was "lopsided".
A government representative has since explained that the US was seeking genetic material for scientific study and profit but refused to share the resulting advantages from any future treatments.
"We will now turn to the challenging and unfortunate task of scaling back our health aid in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy indicated the US had furnished more than $1.9bn in health funding to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has appealed for more negotiations to secure a deal suitable to all parties so the nation's vital HIV programme can continue.
Wider Implications
This rejection follows a similar case in Kenya, where a court halted a similar health funding agreement after legal challenges were raised about the security of Kenyans' medical information.
Since returning to office recently, US President Donald Trump has reduced overseas assistance and shut down the US Agency for International Development (USAID).
The agency had administered aid for the US government, but Trump argued its expenditure was "wasteful" and his government was pursuing government-to-government agreements to boost openness and accountability.
Based on reports, 16 nations in Africa have to date signed these new agreements, representing over $18.3bn in new funding.
Specifics of the Rejected Deal
The funds for Zimbabwe was intended to gone towards "tackling HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this cooperation could have provided significant benefits for the people of Zimbabwe, especially the 1.2 million men, women and children presently receiving antiretroviral therapy via US-supported initiatives," the Ambassador said.
However, government spokesperson Nick Mangwana said the proposed deal was "asymmetrical".
"The proposal required Zimbabwe to share its biological resources and data over an extended period, without any corresponding guarantee of benefiting from any medical innovations – like new medicines or tests – that might be developed from that shared data," Mangwana explained.
"Effectively, our country would supply the raw materials for medical research with no certainty that the end products would be available to our citizens if a new disease outbreak emerge."
Sovereignty and International Frameworks
Mangwana further noted that the US's withdrawal from the World Health Organization (WHO) and its pursuit of one-on-one deals were undermining systems already set up through the global health agency.
The spokesperson gave as an example its Pandemic Benefit-Sharing system created to deal with potential pandemics.
"This mechanism is designed to guarantee that when a country provides its information, the resulting advantages – including medicines and cures – are shared equitably, not commercialised solely by those with the funds to develop them."
The government's concerns over the US deal "are not meant as opposition to America," he added.
"We are open to further dialogue with our American counterparts on how subsequent collaboration might be arranged in a way that respects the independence and dignity of each country."
Health Experts Reaction
Medical experts stated it acknowledged the official position, but recommended that talks need to persist considering much of the nation's HIV programmes depended on international support.
"Where specific concerns arise, such as those relating to data governance or implementation frameworks, these can frequently be addressed via technical clarification and negotiated safeguards," the group commented.
The situation highlights the complex tensions between receiving much-needed international aid and safeguarding local interests in an ever more data-driven world.